Biotech Startups

Citryll is a clinical-stage biotech developing CIT-013, an antibody therapy that targets extracellular traps by selectively binding citrullinated histones to both inhibit new trap formation and clear existing ones. The company is advancing clinical programs in immune-mediated inflammatory diseases, with a current focus on rheumatoid arthritis and hidradenitis suppurativa.

6 investors

Condor is an enterprise-grade financial cloud platform purpose-built for accounting, finance, clinical operations, and FP&A teams in biopharma companies. The platform automates financial workflows and integrates with existing systems to accelerate clinical trial execution and bring therapies to patients faster.

6 investors

VIB is a non-profit research institute focused on strategic basic research in life sciences, operating in partnership with five Flemish universities.

6 investors

Cortical Labs develops biological computing systems by growing human neurons on chips to create a programmable computing platform. The company serves researchers and innovators seeking to accelerate medical research, reduce energy consumption in computing, and enable alternatives to animal testing.

6 investors

Cosyne operates a platform that combines biology, computation, and finance, using a hub-and-spoke model to spin out assets into subsidiaries as a distributed portfolio approach. The company operates laboratories focused on computational and experimental work across London, Cambridge, and New York.

6 investors

Crescendo Biologics develops novel immune cell-enhancing therapeutics for immuno-oncology using its patent-protected Humabody VH platform, a fully human domain technology clinically validated in oncology and immunology. The company collaborates with major pharmaceutical partners including BioNTech and Takeda on drug discovery and development.

6 investors

Crown Bioscience is a contract research organization based in California providing discovery, preclinical, and translational platforms and services for oncology and immuno-oncology drug development. The company serves pharmaceutical and biotech companies seeking to advance and de-risk their drug development programs.

6 investors

CVRx develops Barostim, an implantable medical device that uses baroreceptor activation to treat heart failure patients and improve their functional capacity and quality of life.

6 investors

Cytospire Therapeutics develops multispecific antibodies and next-generation γδ T cell engagers designed to direct innate and adaptive immune effector cells as an alternative to CD3-based engagers. The company is building a portfolio of immune cell engagers aimed at cancer therapies.

6 investors

Dash Bio is a contract research organization (CRO) offering bioanalysis services with a technology-based, automated approach, delivering sample analysis results in days. It provides method development and validation, ELISA/MSD, LC-MS, and qPCR assays across preclinical to late-stage clinical studies for pharmaceutical and biotech companies.

6 investors

Dawaai is a licensed online pharmacy and healthcare group that procures medicines directly from manufacturers and distributors and delivers them to patients' doorsteps, including a two-hour "Fast" delivery service. It operates in Pakistan, serving retail pharmacy customers with pharmacist-handled medicine ordering and delivery.

6 investors

DEM BioPharma is a biotechnology company developing cancer therapies by targeting the immune system, drawing on genetic and immuno-oncology research. The company applies discovery approaches based on academic work in genetics and cancer biology.

6 investors

DermBiont develops SM-030, a topical drug candidate targeting melasma, a skin pigmentation disorder, by inhibiting PKC-beta to address the underlying cause of hyperpigmentation.

6 investors

Design Therapeutics is a biopharmaceutical company developing small molecule therapeutic candidates for serious genetic diseases through its GeneTAC (Gene Targeted Chimera) platform. Its pipeline focuses on monogenic repeat expansion disorders such as Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy, and Huntington's disease.

6 investors

Dewpoint Therapeutics develops condensate-modulating drugs by using an integrated platform that maps, measures, and modulates biomolecular condensates to identify druggable targets and disease mechanisms. Its discovery engine combines biology, chemistry, proprietary datasets, and AI to pursue therapies for complex diseases, including previously undruggable targets.

6 investors

DNA Script develops enzymatic DNA synthesis technology, producing nucleic acids for research and biotech applications. The page lists the company's leadership, board members, and staff.

6 investors

DUDE CHEM develops computational chemistry and digitalization tools for sustainable chemical manufacturing, using green chemistry principles to reduce waste and hazardous substances in the production of chemicals, starting materials, and pharmaceutical ingredients (APIs).

6 investors

Ecovative grows whole-cut meat alternatives and leather-like materials from mycelium using its AirMycelium indoor cultivation platform, which integrates with existing mushroom farming infrastructure. Its products include MyBacon, a sliceable vegan bacon sold in over 3,000 US retail stores, and Forager, a mycelium-based leather substitute in development for fashion and electronics brands.

6 investors

Edgewise Therapeutics discovers and develops small molecule medicines targeting muscle proteins to treat neuromuscular and cardiac diseases, including sevasemten for muscular dystrophies and EDG-7500 for cardiomyopathy, leveraging a proprietary drug discovery platform based on muscle physiology and high-throughput functional assays.

6 investors

eFFECTOR Therapeutics was a clinical-stage biopharmaceutical company. The company is no longer operating.

6 investors

Elegant Bio develops DNA synthesis technology and services, offering ENFINIA™ DNA synthesis at scale for biotech and research applications.

6 investors

Element Biosciences develops biological analysis platforms and DNA sequencing tools for scientists and research institutions. The company serves a global customer base across 40+ countries in the life sciences and genomics industry.

6 investors

Enara Bio discovers and validates Dark Antigens from non-coding genomic regions to identify novel cancer targets, and develops first-in-class bispecific T-cell engagers against these targets through its EnTiCE platform. The company serves cancer patients and collaborates with pharmaceutical companies and academic research institutions.

6 investors

Enlaza Therapeutics develops covalent protein therapeutics using its War-Lock technology, which incorporates proprietary unnatural amino acids into protein drugs so they form irreversible covalent bonds with disease-related targets. The company applies this synthetic biology platform to engineer biologics with improved efficacy and safety for treating cancer and other serious diseases.

6 investors